Biosimilars Bi-weekly Update – February 27, 2017
IHE Life Sciences Open Innovation Platform™ –
What's new and exciting: Top three supported ideas!
- Using existing infrastructure to track outcomes
utilize existing health IT infrastructure to track biosimilar utilization and outcomes, as opposed to creating separate national or multiple provincial patient registries
- Avoid non-medical switching
no non-medical switching of innovator biologics to biosimilars until there is unequivocal evidence supporting its safety
- Robust patient engagement
support an environment of robust patient association involvement in this discussion to understand how this affects individuals beyond the clinic
One month left to provide feedback for the IHE forum at the CADTH 2017 meeting!
If you have an idea, or wish to provide feedback for any existing ideas, logon to the IHE Life Sciences Open Innovation Platform™. Your input is welcome and greatly appreciated!
Register or logon here: IHE Life Sciences Open Innovation Platform™